Want to see IN:VALIANTLAB full AI Analyst Report?
VALIANTLAB Stock Chart & Stats
₹73.50
-₹2.57(-2.33%)
At close: 4:00 PM EST
₹73.50
-₹2.57(-2.33%)
Day’s Range― - ―
52-Week Range₹47.60 - ₹99.31
Previous CloseN/A
Volume41.92K
Average Volume (3M)1.58K
Market Cap
₹3.27B
Enterprise Value₹4.04K
Total Cash (Recent Filing)₹331.50M
Total Debt (Recent Filing)₹462.12M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Aug 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding54,312,500
10 Day Avg. Volume2,243
30 Day Avg. Volume1,577
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.06
Price to Sales (P/S)1.39
P/FCF Ratio-6.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Equity-backed Balance SheetModest leverage and a sizable equity base provide a durable financial buffer that lowers refinancing risk and preserves strategic optionality. This capital structure supports continued investment in API capacity or regulatory compliance while the company works to restore profitability and cash generation.
Meaningful Revenue ReboundA strong FY2026 revenue recovery signals resilient end-market demand or regained customer traction in APIs. Sustained top-line recovery creates room for operating leverage to restore margins, supports fixed-cost absorption, and is a constructive structural signal if customer relationships and order flow persist.
API Manufacturing Business ModelSpecialized API manufacturing is a durable business with structural demand from finished-drug makers and regulatory barriers to entry. Expertise, compliance capabilities and long-term contracts can create sticky revenue streams and competitive moats versus generalist manufacturers over multiple quarters.
Bears Say
Weak Cash GenerationPersistent negative operating and free cash flows point to structural cash burn or elevated capex/inventory requirements. Continued cash deficits increase reliance on external funding, constrain the ability to invest in capacity or R&D, and raise long-term solvency and liquidity concerns if not reversed.
Deteriorated ProfitabilitySwitching from previous multi-year profits to near‑break‑even or negative earnings indicates margin pressure or cost base misalignment. Sustained weak profitability undermines reinvestment capacity, reduces resilience to pricing pressure, and makes long-term returns on capital uncertain without structural margin improvement.
Volatile Historical ReturnsLarge swings in historical returns suggest cyclical or execution risk in the business model. Such volatility can impair creditor and customer confidence, complicate long-range planning and budgeting, and make future investment or contract negotiations more difficult absent demonstrable stability.
Valiant Laboratories Ltd. News
VALIANTLAB FAQ
What was Valiant Laboratories Ltd.’s price range in the past 12 months?
Valiant Laboratories Ltd. lowest stock price was ₹47.60 and its highest was ₹99.31 in the past 12 months.
What is Valiant Laboratories Ltd.’s market cap?
Valiant Laboratories Ltd.’s market cap is ₹3.27B.
When is Valiant Laboratories Ltd.’s upcoming earnings report date?
Valiant Laboratories Ltd.’s upcoming earnings report date is Aug 10, 2026 which is tomorrow.
How were Valiant Laboratories Ltd.’s earnings last quarter?
Valiant Laboratories Ltd. released its earnings results on May 14, 2026. The company reported ₹0.32 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Valiant Laboratories Ltd. overvalued?
According to Wall Street analysts Valiant Laboratories Ltd.’s price is currently Overvalued.
Does Valiant Laboratories Ltd. pay dividends?
Valiant Laboratories Ltd. does not currently pay dividends.
What is Valiant Laboratories Ltd.’s EPS estimate?
Valiant Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valiant Laboratories Ltd. have?
Valiant Laboratories Ltd. has 54,312,500 shares outstanding.
What happened to Valiant Laboratories Ltd.’s price movement after its last earnings report?
Valiant Laboratories Ltd. reported an EPS of ₹0.32 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.028%.
Which hedge fund is a major shareholder of Valiant Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:VALIANTLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valiant Laboratories Ltd.
Valiant Laboratories Limited, an India-based company, specializes in the production of active pharmaceutical ingredients (APIs) and bulk drugs, serving both domestic and international markets. Its primary product is paracetamol, manufactured in various grades that meet Indian, British, European, and United States pharmacopoeia standards. This crucial compound is utilized in treatments for common ailments such as headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. Beyond pharmaceuticals, the company also supplies specialty chemicals. Originally established in 1980 and headquartered in Mumbai, India, the firm rebranded as Valiant Laboratories Limited in August 2021, having previously operated under the name Bharat Chemicals. It functions as a subsidiary of Dhanvallabh Ventures LLP.
Technical Analysis
Albert David Ltd
―
Bafna Pharmaceuticals Limited
―
Medicamen Biotech Limited
―
Medico Remedies Ltd.
―
Zim Laboratories Ltd.
―